Press Releases

RICHMOND, Va., Jun 18, 2002 (BW HealthWire) -- Insmed Incorporated (Nasdaq: INSM) today announced that three abstracts will be presented at The Endocrine Society's 84th Annual Meeting, ENDO 2002, detailing recent research with two of its lead compounds, SomatoKine® and INS-1. David Clemmons, M.D., one of Insmed's lead investigators and Chief, Division of Endocrinology, University of North Carolina, and Charles Mobbs, Ph.D., Associate Professor of Neurobiology at Mt. Sinai School of Medicine, will give poster presentations revealing their research involving SomatoKine and INS-1 respectively. 

The abstracts to be presented follow, and may be viewed in full at the website www.abstracts-on-line.com/abstracts/Endo. 

Wednesday, June 19: 

P1-277: IGF-1/IGF-BP3 (SomatoKine) Combination Improves Insulin Resistance by GH Dependent and GH Independent Mechanisms 

Friday, June 21: 

P3-554: Recombinant Human IGFBP-3 is Preferentially Degraded in Humans In Vivo and Administration of rhIGFBP-3 to Diabetics Results in an Increase in the Concentration of Glycosylated Human IGFBP-3 

P3-391: D-Chiro-Inositol (INS-1) Modulates the Effects of Gold-Thio-Glucose and Diet on Body Weight and Glucose Tolerance: Genetic Influences 

The 84th Annual Meeting of the Endocrine Society is taking place at the Moscone Convention Center, in San Francsico, from Wednesday, June 19 until Saturday, June 22. The posters will be available for review 9:30a.m. to 4:00 p.m. The presenters will be available for discussion from 11:00 a.m. to 12:00 noon and from 2:30 to 3:30 p.m. 

About INS-1 

Insmed's orally active insulin sensitizer addresses large, unmet medical needs. An estimated 135 million people worldwide suffer from diabetes, with annual diabetes, health-related expenditures reaching $100 billion in the United States alone. Worldwide sales of the top three oral insulin sensitizers, GLUCOPHAGE, ACTOS and AVANDIA marketed by Bristol-Myers Squibb (NYSE:BMY), Eli Lilly (NYSE:LLY) and GlaxoSmithKline (NYSE:GSK) respectively, exceeded $4 billion in 2001. Despite this strong demand for these existing agents, most have less than optimal side effect profiles, creating a significant market opportunity for INS-1. In patients with type 2 diabetes, INS-1 significantly improves glycemic and lipid profiles with no evidence of any major side effects. The company is also pioneering INS-1 as a treatment for polycystic ovary syndrome (PCOS), a significant women's health disorder that currently has no approved therapies that address the underlying cause of the disorder. 

About SomatoKine® 

The company's product candidate, SomatoKine®, is being developed as an injectable insulin sensitizer and growth promoting agent. The drug is the recombinant equivalent of human insulin-like growth factor-I (IGF-I) and its primary binding protein, IGFBP-3. SomatoKine is currently in clinical development for type 1 and type 2 diabetes, severe burn injury, and growth hormone insensitivity syndromes (GHIS), and will initiate clinical trials by years end in myotonic muscular dystrophy (MMD) and AIDS Lipodystrophy. Insmed has received orphan drug designation for severe burn injury. 

About Insmed Incorporated 

Insmed Incorporated is a biopharmaceutical company focused on the development of drug candidates for the treatment of metabolic diseases. Further information is available at /www.insmed.com. Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements regarding expected financial position, results of operations, cash flows, dividends, financing plans, business strategies, operating efficiencies or synergies, budgets, capital and other expenditures, competitive positions, growth opportunities for existing or proposed products or services, plans and objectives of management, demand for new pharmaceutical products, market trends in the pharmaceutical business, inflation and various economic and business trends. Such forward-looking statements are subject to numerous risks and uncertainties, including risks that product candidates may fail in the clinic or may not be successfully marketed, the company may lack financial resources to complete development of product candidates, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release. 

CONTACT: Insmed Incorporated Baxter Phillips, III, 804/565-3041 bphillips@insmed.com